Pharma M&A up 500% in Q1; Lexicon advancing diabetes drug;

@FierceBiotech: Special report: Which Big Biotechs are hitting the gas pedal on R&D spending? Feature | Follow @FierceBiotech

@JohnCFierce: Looks like Takeda management maybe in for more changes. The numbers are awful. Report | Follow @JohnCFierce

@RyanMFierce: My story on how industry legend Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups. Article | Follow @RyanMFierce

> Hutchison China MediTech is planning to license its cancer treatment fruquintinib, which is based on traditional Chinese medicines. Story

> Santarus ($SNTS) has unveiled a secondary underwritten public offering of 4,250,000 shares of its common stock at a price to the public of $18.25 per share on behalf of shareholder Cosmo Technologies. Release

> Salix has made an appeal to the FDA for a July 2012 complete response letter for an sNDA for subcutaneous Relistor methylnaltrexone to treat opioid-induced constipation (OIC) in patients with non-cancer pain. Item

> The ALS Emergency Treatment Fund and Denovo Biomarkers have formed a partnership to look for genomic biomarkers that correlate with ALS patients' responsiveness to treatment. Release

> Lexicon Pharmacueticals ($LXRX) is advancing its drug LX4311 to a Phase II clinical trial in patients with type 1 diabetes. Release

> The value of pharmaceutical M&A in Q1 2013 was up more than 500% from the same quarter a year ago, according to a new PwC report. More

Medical Device News

@FierceMedDev: Boston Scientific: Watchman beats warfarin in follow-up. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim's leadless pacer has had some success in early human trials. Future buyer St. Jude Medical must be pleased. Story | Follow @MarkHFierce

 @DamianFierce: St. Jude: Independent analysis says Durata leads are safe, reliable. Report | Follow @DamianFierce

> CareFusion's revenue slips 2%. Item

> U.K. pair challenges earlier finding that substandard PIP breast implants were safe. Report

> Quest settles New York case over illegal hiring practices. Story

Pharma News

@FiercePharma: WSJ: J&J's multibillion-$$ Risperdal settlement snags on breast side effects. $JNJ worried a/b civil suits. Article | Follow @FiercePharma

 @EricPFierce: Pharma M&A way up in Q1 2013 compared to a year ago. Value up more than 500%. Feature | Follow @EricPFierce

> AbbVie, Pfizer's Zoetis deals ignite enormous leap in M&A value. Report

> Motherhood at center of Merck gender bias suit. Article

> Amgen forges Chinese JV for Vectibix. Story

And Finally… NIH's 2013 budget is out. As expected, sequestration chopped the agency's budget by $1.55 billion to a total of $29.15 billion for the year, a 5% cut. Story

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.